




# **Cysteine-proteases inhibitors for Infectious Diseases**

UNIVERSITAT  
JAUME I

# Dept. Química Inorgànica i Orgànica (U.J.I.)

<http://orgmedchem.uji.es>




- Organic synthesis: synthetic methodology, synthesis of natural products
- Medicinal Chemistry: design and synthesis of cysteine proteases inhibitors



# Chagas' disease


- 16 -18 millions in Latin-America, 50.000 deaths/yr., 90 millions under risk.
- Caused by protozoa *Trypanosoma cruzi*.
- The transmitter agent is *Triatoma* beetle.
- Cardiopathies, digestive lesions and neurological disorders, finally heart attack.
- The used drugs (benznidazole and nifurtimox) low efficient and secondary effects.





# Sleeping sickness

- Half a million of people in Subsaharian Africa, 70 millions under risk.
- Caused by protozoa *Trypanosoma brucei*.
- The transmitter agent is tse-tse fly.
- Immunodeficiency, anemia and cardiac and endocrine disorders, and finally coma and death.
- The only drug (melarsoprol) is highly toxic.





# Malaria

- Almost 40% of world population affected
- More than 3.000 millions under risk
- Caused by protozoa *Plasmodium falciparum*
- The transmitter agent is *Anopheles* mosquito
- The used drugs chloroquine and mefloquine show side effects and there is no total protection
- In Spain: 450 cases/yr. since 2000

# TARGETS

## Cysteine proteases from papain superfamily

**Cruzain** (*Trypanosoma cruzi*)

(Chagas)

**Rhodesain** (*Trypanosoma brucei*)

(African trypanosomiasis)

**Falcipain** (*Plasmodium falciparum*)


(Malaria)

**EhCP1** (*Entamoeba histolytica*)

(Amebiasis)

**CP2** (*Giardia lamblia*)

(Giardiasis)




## Highly potent irreversible cysteine proteases inhibitors

**IC<sub>50</sub> (nM)**

Comp	Cruzain	Rhodesain	T.b.CathepsinB
Q073	20	3.5	>>1000
Q074	50	30	400

**Patente: P200701717.**  
**PCT: PCT/ES2008/070116**  
**Bioorg. Med. Chem. Lett. 2007, 17, 6697-6700.**

# Developing of inhibitors



*In vivo* biological assays (U.C.M.)



**Drug**

# Acknowledgements

**Javier Izquierdo (UJI)**  
**Santiago Rodríguez (UJI)**  
**James H. McKerrow (UCSF)**  
**Elizabeth Hansell (UCSF)**



**Generalitat Valenciana (GV05/071)**  
**Bancaixa-UJI foundation (P1 1A2005-14)**  
**Genoma España**